'No longer viable': York pharmacies to merge amid spiralling staff costs

Two York pharmacies are set to merge, with staff costs at a 100-hour branch making the site “no longer viable”, a pharmacy group based in the city has said.

York city
100-hour pharmacy to move onto site of 40-hour pharmacy, which will open for 66 hours

Richard Harrison, director of independent pharmacy group Citywide Health, told C+D yesterday (May 24) that the pharmacy’s rent at a health centre was also a “significant” cost.

Free to registered users

Register to gain full access to C+D and C+D Community content

Sign in or register for free

James Stent

Read more by James Stent

James Stent joined C+D as a digital reporter in May 2023 from the South African human rights news agency GroundUp, where he was senior reporter and consultant editor.

Latest from News

Retired pharmacist crushed to death in canal boat accident

 
• By 
 • comment

Margaret Billings sustained fatal injuries when she was caught between a moving boat and a riverbank during a day out “with family and friends”, an inquest has found.

NHSE scrapped: ‘Fresh start or just more political chaos?’

 
• By 
 • comment

C+D rounds up some of the immediate pharmacy reaction to news that NHS England will be abolished, with more control moving back to the government and local leaders…

New primary care medical director role as 2-year NHSE axing begins

 
• By 
 • comment

Wes Streeting has revealed that the DH is “immediately” working to scrap NHS England (NHSE) and put a new “transformation team” in place – adding that it is in the “very final stages” of concluding a new pharmacy contract deal.

More from Business

breaking news

IN FULL: Boots’ parent company sold in $24bn private equity deal

 
• By 
 • comment

Walgreens Boots Alliance (WBA) has “entered into a definitive agreement to be acquired” by private equity firm Sycamore Partners.

Jhoots accounts: Shareholder funds tumble while debts soar

 
• By 
 • comment

Jhoots Chemist’s accounts for 2024 have revealed an almost £2 million year-on-year dip in shareholder funds – as debts to creditors increase more than £2m.